Study Overview

Aim

The overall aim of this study is to deliver a snapshot of investigative and management practice for patients with newly identified pancreatic cancer and malignant biliary obstruction.

Hypothesis

There are wide variations in investigative and management practices for patients with hepaticopancreatobiliary (HPB) malignancy. These variations affect patient outcomes.

Primary Objective

Our primary objective is to describe the management pathways and 90-day outcomes for patients who are investigated for resectable and un-resectable HPB malignancies.

Patient Selection

Any patient with a pancreatic lesion suspected of being malignant and/or those with malignant biliary obstruction caused by a malignancy of the extra-hepatic biliary tree will be included.

​

Patients will be excluded if they are under sixteen years of age or have suspected recurrent or secondary HPB malignancy.

​

Patients will be identified by cancer-specific MDT, clinical nurse specialists and biliary decompression lists. 

Data Collection

Case identification will run for 90 days with a 90 day follow up for each patient from the date of their initial presentation.

​

Data will be collected via direct upload to secure, electronic database REDCap. 

Authorship

We have a corporate authorship policy which will be 'The RICOCHET Study Group on behalf of the West Midlands Research Collaborative'. 

Collaborators will be recognised according to their input with the study. 

​

All authorship is PubMed citeable.